Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Cleminorexton in Narcolepsy and Idiopathic Hypersomnia
2025-522987-34-00Phase 3Authorised
- Sponsor
- Centessa Pharmaceuticals
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of cleminorexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and hypersomnolence disorder, sponsored by Centessa Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events, Laboratory safety parameters and 3 more. Planned start Feb 2026; status: authorised.
02
Drugs
cleminorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)hypersomnolence disorder
Beyond the preview
Go deeper on 2025-522987-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522987-34-00.